Phathom Pharmaceuticals, a leading biopharmaceutical company focused on gastrointestinal diseases, has recently announced the inclusion of VOQUEZNA (vonoprazan) tablets in the Express Scripts national formularies. This development provides a significant breakthrough in the treatment of Erosive Esophagitis, commonly known as Erosive GERD, and offers relief from associated heartburn, marking the introduction of a new class of medications for these conditions within the United States after a three-decade gap.
VOQUEZNA is the first FDA-approved potassium-competitive acid blocker (PCAB), presenting a novel approach to managing Erosive GERD. By effectively reducing acid secretion in the stomach, these tablets alleviate symptoms and aid in the healing of the esophagus. With this addition to the national formularies, an estimated 60 million covered lives in the United States will now be able to access VOQUEZNA tablets for the treatment of Erosive GERD and associated heartburn.
The introduction of VOQUEZNA represents a significant milestone for individuals suffering from Erosive GERD, as current treatment options have remained stagnant for over 30 years. This innovative medication offers hope and relief to the millions of Americans who grapple with the debilitating symptoms of this condition.
Phathom Pharmaceuticals’ focus on developing and commercializing novel treatments for gastrointestinal disorders highlights their commitment to addressing unmet medical needs. With the inclusion of VOQUEZNA in the Express Scripts formularies, patients across the country will gain increased access to this transformative treatment, improving their quality of life.
In conclusion, the addition of VOQUEZNA tablets to the Express Scripts national formularies marks a significant advancement in the treatment of Erosive GERD and associated heartburn in the United States. This FDA-approved medication offers a new class of treatment options after a long gap, positively impacting the lives of millions of affected individuals nationwide. Through Phathom Pharmaceuticals’ commitment to innovation, patients now have access to greater relief and improved management of their gastrointestinal health.
Comments